original ) (raw )Indacaterol 75 μg: COPD patients’ perceived onset
Dove Medical Press
2014
View PDFchevron_right
Bronchodilator efficacy of indacaterol, a novel once-daily β2-agonist, in patients with persistent asthma
David Pearlman
Annals of Allergy, Asthma & Immunology, 2008
View PDFchevron_right
Long-term Safety and Efficacy of Indacaterol, a Long-Acting b2-Agonist, in Subjects With COPD A Randomized, Placebo-Controlled Study
Kenneth Chapman
View PDFchevron_right
Long-term safety and efficacy of indacaterol, a long-acting beta-agonist, in subjects with COPD: a randomized, placebo-controlled study.
Kenneth Chapman
View PDFchevron_right
Effect of an additional dose of indacaterol in COPD patients under regular treatment with indacaterol
E. Puxeddu , Josuel Ora
Respiratory Medicine, 2013
View PDFchevron_right
Efficacy and safety of indacaterol 150 μg once-daily in COPD: a double-blind, randomised, 12-week study
Mark Higgins
BMC Pulmonary Medicine, 2010
View PDFchevron_right
Safety of indacaterol in the treatment of patients with COPD
James Donohue
International Journal of Chronic Obstructive Pulmonary Disease, 2011
View PDFchevron_right
The effect of indacaterol during an acute exacerbation of COPD
P. Rogliani , M. Cazzola , Marco Sabatini
Pulmonary Pharmacology & Therapeutics, 2013
View PDFchevron_right
A real-world evaluation of indacaterol and other bronchodilators in COPD: the INFLOW study
Chaicharn Pothirat
International Journal of Chronic Obstructive Pulmonary Disease, 2015
View PDFchevron_right
Sustained 24-hour efficacy of once daily indacaterol (300 μg) in patients with chronic obstructive pulmonary disease: A randomized, crossover study
AMIR IQBAL
Pulmonary Pharmacology & Therapeutics, 2011
View PDFchevron_right
The impact of treatment with indacaterol in patients with COPD: A post-hoc analysis according to GOLD 2011 categories A to D
James Donohue
Pulmonary pharmacology & therapeutics, 2015
View PDFchevron_right
Comparative efficacy of indacaterol in chronic obstructive pulmonary disease
Kenneth Chapman
International journal of chronic obstructive pulmonary disease, 2012
View PDFchevron_right
Role of indacaterol, a once-daily bronchodilator, in chronic obstructive pulmonary disease
Samir Sultan
Journal of thoracic disease, 2013
View PDFchevron_right
Role of indacaterol and the newer very long-acting β2-agonists in patients with stable COPD: a review
Cristoforo Incorvaia
International Journal of Chronic Obstructive Pulmonary Disease, 2013
View PDFchevron_right
Single- and multiple-dose pharmacokinetics of inhaled indacaterol in healthy Chinese volunteers
Tobias Welte
European Journal of Drug Metabolism and Pharmacokinetics, 2014
View PDFchevron_right
Indacaterol provides sustained 24 h bronchodilation on once-daily dosing in asthma: a 7-day dose-ranging study
Craig Laforce
Allergy, 2007
View PDFchevron_right
Indacaterol therapy in moderate-to-severe chronic obstructive pulmonary disease: findings from a single-center primary care cohort
Mukesh Singh
International journal of chronic obstructive pulmonary disease, 2013
View PDFchevron_right
24-h bronchodilator efficacy of single doses of indacaterol in Japanese patients with asthma: A comparison with placebo and salmeterol
Masakazu Ichinose
Respiratory Medicine, 2010
View PDFchevron_right
Efficacy and safety of indacaterol 150 and 300 µg in chronic obstructive pulmonary disease patients from six Asian areas including Japan: A 12-week, placebo-controlled study
Masakazu Ichinose
Respirology, 2012
View PDFchevron_right
Assessing efficacy of indacaterol in moderate and severe COPD patients: a 12-week study in an Asian population
Niyati Prasad
Respiratory medicine, 2012
View PDFchevron_right
Indacaterol: A Novel Long-Acting β2-Agonist
Andrea Franks
Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2012
View PDFchevron_right
Efficacy of a new once-daily long-acting inhaled 2-agonist indacaterol versus twice-daily formoterol in COPD
Kian Chung
Thorax, 2010
View PDFchevron_right
Once-daily long-acting beta-agonists for chronic obstructive pulmonary disease: an indirect comparison of olodaterol and indacaterol
N. Roskell , Alan Hamilton , Bernd Disse
International Journal of Chronic Obstructive Pulmonary Disease, 2014
View PDFchevron_right
Systematic review comparing LABA, olodaterol, and indacaterol: limitations
James Donohue
International journal of chronic obstructive pulmonary disease, 2014
View PDFchevron_right
QVA149 demonstrates superior bronchodilation compared with indacaterol or placebo in patients with chronic obstructive pulmonary disease
Joaquim Moita
View PDFchevron_right
Effect of indacaterol, a novel long-acting 2-agonist, on isolated human bronchi
Emmanuel Naline
European Respiratory Journal, 2007
View PDFchevron_right
Once-daily indacaterol versus tiotropium for patients with severe chronic obstructive pulmonary disease (INVIGORATE): a randomised, blinded, parallel-group study
Kenneth Chapman
The Lancet. Respiratory medicine, 2013
View PDFchevron_right
About the Role of Indacaterol in Obstructive Airways Disorder: CON
Marta Drummond
2012
View PDFchevron_right
Acute effects of indacaterol on lung hyperinflation in moderate COPD: A comparison with tiotropium
Stefano Centanni
2012
View PDFchevron_right
Long-term Triple Therapy De-escalation to Indacaterol/Glycopyrronium in COPD Patients (SUNSET): a Randomized, Double-Blind, Triple-Dummy Clinical Trial
Kenneth Chapman
American journal of respiratory and critical care medicine, 2018
View PDFchevron_right
Effectiveness of Indacaterol-Glycopyrronium in preventing COPD exacerbations in comparison to Salmeterol-Fluticasone
Ashiq Choudhury
Bangabandhu Sheikh Mujib Medical University Journal, 2022
View PDFchevron_right
Indacaterol/glycopyrronium reduces the risk of clinically important deterioration after direct switch from baseline therapies in patients with moderate COPD: a post hoc analysis of the CRYSTAL study
Veronica Pagano
International Journal of Chronic Obstructive Pulmonary Disease, 2018
View PDFchevron_right
Once-Daily Bronchodilators for Chronic Obstructive Pulmonary Disease
Amir iQbal
American Journal of Respiratory and Critical Care Medicine, 2010
View PDFchevron_right
Indacaterol/Glycopyrronium Combination for COPD
Josuel Ora
Pulmonary Therapy, 2017
View PDFchevron_right
A dose-ranging study of indacaterol in obstructive airways disease, with a tiotropium comparison
Stefano Centanni
Respiratory Medicine, 2008
View PDFchevron_right